The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Freezing of Gait Program, 2025Treating Freezing of Gait in Parkinson’s Disease Using an ADHD Drug that Reduces Neural Cross-talk: A Multi-center Multi-modal Approach
Study Rationale: Freezing of gait affects four out of five people with Parkinson’s disease (PD), yet this debilitating symptom is not fully treated by any PD medication available. Research has shown...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessment of Psilocybin Therapy for Treatment of Depression in Parkinson’s Disease
Study Rationale: Depression is of the most common and disabling symptoms of Parkinson’s disease (PD), and it is linked to poor quality of life and faster disease progression. Unfortunately, we lack...
-
Research Grant, 2025The BioFINDER Studies: Identifying Disease Stages and Effects of Co-morbidities in Neuronal Synuclein Disease
Study Rationale: Neuronal synuclein disease (NSD) is the underlying cause of Parkinson’s disease (PD) and similar disorders. Recently, new tests have allowed us to measure signs of NSD before symptoms...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Investigation of a Novel Therapeutic Approach for Non-motor Symptoms of Parkinson’s Disease
Study Rationale:
Parkinson's disease (PD) is characterized by both motor symptoms and non-motor symptoms. While progress has been made in addressing motor symptoms, non-motor...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
Study Rationale: Although levodopa is an effective treatment for Parkinson’s disease (PD), it has a debilitating on-target side effect of dyskinesia. An optimal PD therapy would selectively activate...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessing the Safety and Efficacy of a Novel Enzyme Inhibitor in Reducing Neuroinflammation and Enhancing Neuroprotection in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by neuroinflammation and the loss of dopamine neurons. Recently, epoxy-fatty acids have been shown to be neuroprotective in preclinical...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.